Tarek Ammar, MD
Gastroenterology · Las Vegas, NVNPI 1649478314
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.0%.
Across 343 payments — averaging $39.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nestle Healthcare Nutrition Inc.$3K
- AbbVie$3K
- Boston Scientific$2K
- QOL Medical, LLC$2K
- Endogastric Solutions, Inc$709
- Olympus Corporation Of The Americas$608
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$3,90029%
- Travel & lodging$2,08515%
- Food & beverage$7,40855%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nestle Healthcare Nutrition Inc. | 15 | $2,829 |
| AbbVie(2 entities) | 143 | $2,578 |
| Boston Scientific | 17 | $1,835 |
| QOL Medical, LLC | 13 | $1,599 |
| Endogastric Solutions, Inc | 5 | $709 |
| Olympus Corporation Of The Americas | 9 | $608 |
| Johnson & Johnson(2 entities) | 21 | $529 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $491 |
| Gilead | 18 | $456 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $330 |
| Olympus America Inc. | 3 | $317 |
| Braintree Laboratories, Inc. | 8 | $129 |
| Cook Medical LLC | 1 | $119 |
| Ironwood Pharmaceuticals, Inc | 5 | $103 |
| Medivators Inc. | 1 | $86 |
| Merck | 4 | $79 |
| Alfasigma USA, Inc. | 4 | $75 |
| Pfizer | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Shire North American Group Inc | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $61 |
| Lucid Diagnostics Inc. | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Redhill Biopharma Inc. | 2 | $37 |
| Intercept Pharmaceuticals, Inc. | 2 | $34 |
| Orphalan Inc | 1 | $29 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Bristol Myers Squibb | 1 | $24 |
| Sanofi | 1 | $23 |
| Intra-sana Laboratories | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $13 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$2,630
- Sucraid$1,400
- ORISE$696
- ESOPHYX$627
- Olympus EMR & ESD Devices$482
- Olympus Hemostasis Devices$482
- Olympus EndoTherapy Accessories$482
- OverStitch NXT Endoscopic Suturing System$349
- SpaceOAR VUE System - 10mL$175
- OER-PRO$149
- Olympus EUS Devices$130
- LINX Reflux Management System$125
- Instinct$119
- GENERAL - THERAPIES$116
- GENERAL HEMOSTASIS$108
How this compares
$13,505 in reported general payments places this provider in the 85th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $80,135 |
| ZenpepLipase/Protease/Amylase | 16 | $77,845 |
| LinzessLinaclotide | 39 | $31,754 |
| MounjaroTirzepatide | 14 | $14,289 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 70 | $4,768 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 29 | $4,691 |
| Omeprazole | 345 | $3,587 |
| Sucralfate | 12 | $1,358 |
| Pantoprazole Sodium | 61 | $797 |
| Famotidine | 81 | $737 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 43 | $500 |
| Nortriptyline Hcl | 38 | $423 |
| Dicyclomine Hcl | 27 | $312 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $274 |
| Lactulose | 13 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,578 | $111,88961 claims |
| Aimmune Therapeutics, Inc.Zenpep | $43 | $77,84516 claims |
| Braintree Laboratories, Inc.Sutab | $129 | $4,69129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Eladio CarreraLas Vegas$13K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.